03 Oct 2017 OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
03 Oct 2017 Ablynx announces positive topline results from the phase III HERCULES study of caplacizumab for the treatment of acquired TTP
03 Oct 2017 Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
03 Oct 2017 Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
30 Sep 2017 Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference
29 Sep 2017 Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
29 Sep 2017 FDA Grants Priority Review for Genentech’s Perjeta® (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
28 Sep 2017 Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
28 Sep 2017 AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen
28 Sep 2017 Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
28 Sep 2017 MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients
26 Sep 2017 Sonnet Biotherapeutics to present data on bispecific platform candidates at AACR and SITC Annual Meetings
26 Sep 2017 argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris
25 Sep 2017 Infinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab)
25 Sep 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
24 Sep 2017 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1)
24 Sep 2017 Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application
24 Sep 2017 Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib
22 Sep 2017 Roche receives European approval for Actemra /RoActemra in giant cell arteritis
22 Sep 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
22 Sep 2017 AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors
22 Sep 2017 Eisai presents latest non-clinical data on its first antibody-drug conjugate MORAb-202 at 8th Annual World ADC
21 Sep 2017 Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
21 Sep 2017 MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3 Studies with TremfyaTM (Guselkumab) in Psoriatic Arthritis
21 Sep 2017 European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing